Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology - PubMed (original) (raw)
Review
. 2018 May;20(5):853-872.
doi: 10.1002/ejhf.1170. Epub 2018 Mar 8.
Mark C Petrie 2, Gerasimos S Filippatos [ 3](#full-view-affiliation-3 "Department of Cardiology, National and Kapodistrian University of Athens Medical School, Athens University Hospital "Attikon", Athens, Greece."), Stefan D Anker 4, Giuseppe Rosano 5, Johann Bauersachs 6, Walter J Paulus 7, Michel Komajda 8, Francesco Cosentino 9, Rudolf A de Boer 10, Dimitrios Farmakis 2, Wolfram Doehner 11, Ekaterini Lambrinou 12, Yuri Lopatin 13, Massimo F Piepoli 14, Michael J Theodorakis 15, Henrik Wiggers 16, John Lekakis 2, Alexandre Mebazaa 17, Mamas A Mamas 18, Carsten Tschöpe 19, Arno W Hoes 20, Jelena P Seferović 21, Jennifer Logue 22, Theresa McDonagh 23, Jillian P Riley 24, Ivan Milinković 1, Marija Polovina 1, Dirk J van Veldhuisen 25, Mitja Lainscak 26, Aldo P Maggioni 27, Frank Ruschitzka 28, John J V McMurray 29
Affiliations
- PMID: 29520964
- DOI: 10.1002/ejhf.1170
Free article
Review
Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology
Petar M Seferović et al. Eur J Heart Fail. 2018 May.
Free article
Abstract
The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30-40% of patients) and associated with a higher risk of HF hospitalization, all-cause and cardiovascular (CV) mortality. The most important causes of HF in T2DM are coronary artery disease, arterial hypertension and a direct detrimental effect of T2DM on the myocardium. T2DM is often unrecognized in HF patients, and vice versa, which emphasizes the importance of an active search for both disorders in the clinical practice. There are no specific limitations to HF treatment in T2DM. Subanalyses of trials addressing HF treatment in the general population have shown that all HF therapies are similarly effective regardless of T2DM. Concerning T2DM treatment in HF patients, most guidelines currently recommend metformin as the first-line choice. Sulphonylureas and insulin have been the traditional second- and third-line therapies although their safety in HF is equivocal. Neither glucagon-like preptide-1 (GLP-1) receptor agonists, nor dipeptidyl peptidase-4 (DPP4) inhibitors reduce the risk for HF hospitalization. Indeed, a DPP4 inhibitor, saxagliptin, has been associated with a higher risk of HF hospitalization. Thiazolidinediones (pioglitazone and rosiglitazone) are contraindicated in patients with (or at risk of) HF. In recent trials, sodium-glucose co-transporter-2 (SGLT2) inhibitors, empagliflozin and canagliflozin, have both shown a significant reduction in HF hospitalization in patients with established CV disease or at risk of CV disease. Several ongoing trials should provide an insight into the effectiveness of SGLT2 inhibitors in patients with HFrEF and HFpEF in the absence of T2DM.
Keywords: Glucose-lowering agents; Heart failure; Heart failure hospitalization; Heart failure treatment; Type 2 diabetes mellitus.
© 2018 The Authors. European Journal of Heart Failure © 2018 European Society of Cardiology.
Similar articles
- European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
Seferović PM, Coats AJS, Ponikowski P, Filippatos G, Huelsmann M, Jhund PS, Polovina MM, Komajda M, Seferović J, Sari I, Cosentino F, Ambrosio G, Metra M, Piepoli M, Chioncel O, Lund LH, Thum T, De Boer RA, Mullens W, Lopatin Y, Volterrani M, Hill L, Bauersachs J, Lyon A, Petrie MC, Anker S, Rosano GMC. Seferović PM, et al. Eur J Heart Fail. 2020 Feb;22(2):196-213. doi: 10.1002/ejhf.1673. Epub 2019 Dec 9. Eur J Heart Fail. 2020. PMID: 31816162 - Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes.
Katsiki N, Kazakos K, Triposkiadis F. Katsiki N, et al. Expert Opin Pharmacother. 2022 Dec;23(17):1957-1974. doi: 10.1080/14656566.2022.2143263. Epub 2022 Nov 20. Expert Opin Pharmacother. 2022. PMID: 36322877 Review. - [Type 2 Diabetes Mellitus and Heart Failure: Innovative Possibilities for Management of Prognosis].
Kobalava ZD, Yeshniyazov NV, Medovchshikov VV, Khasanova ER. Kobalava ZD, et al. Kardiologiia. 2019 Apr 17;59(4):76-87. doi: 10.18087/cardio.2019.4.10253. Kardiologiia. 2019. PMID: 31002044 Review. Russian. - The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus.
Asleh R, Sheikh-Ahmad M, Briasoulis A, Kushwaha SS. Asleh R, et al. Heart Fail Rev. 2018 May;23(3):445-459. doi: 10.1007/s10741-017-9666-8. Heart Fail Rev. 2018. PMID: 29270818 Review. - Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms.
Savarese G, Butler J, Lund LH, Bhatt DL, Anker SD. Savarese G, et al. Cardiovasc Res. 2022 Jul 27;118(10):2231-2252. doi: 10.1093/cvr/cvab271. Cardiovasc Res. 2022. PMID: 34390570 Review.
Cited by
- Clinical outcomes in type 2 diabetes patients with chronic heart failure treated with metformin: a meta-analysis.
Huang W, Zhao R. Huang W, et al. Endocrine. 2024 Sep 15. doi: 10.1007/s12020-024-04025-6. Online ahead of print. Endocrine. 2024. PMID: 39277567 Review. - Multi-omics analysis of the lipid-regulating effects of metformin in a glucose concentration-dependent manner in macrophage-derived foam cells.
Qi J, Dong M, Gou Q, Zhu H. Qi J, et al. Cell Biochem Biophys. 2024 Sep 5. doi: 10.1007/s12013-024-01269-x. Online ahead of print. Cell Biochem Biophys. 2024. PMID: 39235508 - Enhancing Comprehensive Assessments in Chronic Heart Failure Caused by Ischemic Heart Disease: The Diagnostic Utility of Holter ECG Parameters.
Duca ȘT, Tudorancea I, Haba MȘC, Costache AD, Șerban IL, Pavăl DR, Loghin C, Costache-Enache II. Duca ȘT, et al. Medicina (Kaunas). 2024 Aug 14;60(8):1315. doi: 10.3390/medicina60081315. Medicina (Kaunas). 2024. PMID: 39202596 Free PMC article. - Effects of SGLT2-Inhibitors on Comprehensive Geriatric Assessment, Biomarkers of Oxidative Stress, and Platelet Activation in Elderly Diabetic Patients with Heart Failure with Preserved Ejection Fraction.
Magurno M, Cassano V, Maruca F, Pastura CA, Divino M, Fazio F, Severini G, Clausi E, Armentaro G, Miceli S, Maio R, Imbalzano E, Andreozzi F, Hribal ML, Sciacqua A. Magurno M, et al. Int J Mol Sci. 2024 Aug 13;25(16):8811. doi: 10.3390/ijms25168811. Int J Mol Sci. 2024. PMID: 39201499 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous